Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. On Wednesday, Amgen Inc (NASDAQ:AMGN) stated the MariTide (maridebart cafraglutide,
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
operates through a different weight loss mechanism. The drug’s development has attracted significant attention due to ...
A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...
Amgen stock soared as much as 16% on Friday after it reported first-quarter earnings. The company talked up its experimental GLP-1 weight-loss drug, MariTide. The new weight loss drug ...
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback